Quest for the right Drug
ריתמונורם 150 מ"ג RYTMONORM 150 MG (PROPAFENONE HYDROCHLORIDE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
טבליות מצופות פילם : FILM COATED TABLETS
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8. Undesirable Effects a. Summary of the safety profile The most frequent and very common adverse reactions related to propafenone therapy are dizziness, cardiac conduction disorders and palpitations. b. Tabulated summary of adverse reactions The following table displays adverse reactions reported in clinical trials and from post-marketing experience with propafenone. The reactions considered at least possibly related to propafenone are displayed by system organ class and frequency using the following convention: very common (≥1/10), common (≥ 1/100 to < 1/10), uncommon (≥1/1,000 to < 1/100) and not known (adverse reactions from post-marketing experience; cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness when the seriousness could be assessed. The frequencies are based on clinical trial data from propafenone SR. It is expected that the adverse reactions and frequencies for IR formulations would be similar. System Organ Very common Common Uncommon Not Known Class ≥1/10 ≥ 1/100 to < 1/10 ≥1/1,000 to < 1/100 (cannot be estimated from the available data) Blood and Thrombocytopenia Agranulocytosis lymphatic system Leukopenia disorders Granulocytopenia Immune system Hypersensitivity1 disorders Metabolism and Decreased appetite nutrition disorders Psychiatric Anxiety Nightmare Confusional state disorders Sleep disorders Nervous system Dizziness2 Headache Syncope Convulsion disorders Dysgeusia Ataxia Extrapyramidal Paraesthesia symptoms Restlessness Eye disorders Vision blurred Ear and labyrinth Vertigo disorders Cardiac disorders Cardiac Sinus bradycardia Ventricular Ventricular conduction Bradycardia tachycardia fibrillation disorders3 Tachycardia Arrythmia4 Cardiac failure5 Palpitations Atrial flutter Heart rate reduced Vascular disorders Hypotension Orthostatic hypotension Respiratory, Dyspnoea thoracic and mediastinal disorders Gastrointestinal Abdominal pain Abdominal Retching disorders Vomiting distension Gastrointestinal Nausea Flatulence disturbance Diarrhoea Constipation Dry mouth Hepatobiliary Hepatic function Hepatocellular injury disorders abnormal6 Cholestasis Hepatitis Jaundice Skin and Urticaria Acute generalized subcutaneous tissue Pruritus exanthematous disorders Rash pustulosis Erythema Musculoskeletal Lupus-like syndrome and connective tissue disorders Reproductive Erectile dysfunction Sperm count system and breast decreased7 disorders General disorders Chest pain and administration Asthenia site conditions Fatigue Pyrexia 1 May be manifested by cholestasis, blood dyscrasias and rash 2 Excluding vertigo 3 Including sinoatrial block, atrioventricular block and intraventricular block 4 Propafenone may be associated with proarrhythmic effects which manifest as an increase in heart rate (tachycardia) or ventricular fibrillation. Some of these arrhythmias can be life- threatening and may require resuscitation to prevent a potentially fatal outcome 5 An aggravation of preexisting cardiac insufficiency may occur 6 This term covers abnormal liver function tests, such as aspartate aminotransferase increased, alanine aminotransferase increased, gamma-glutamyltransferase increased and blood alkaline phosphatase increased 7 Decreased sperm count is reversible upon discontinuation of propafenone Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form http://sideeffects.health.gov.il
שימוש לפי פנקס קופ''ח כללית 1994
Life-threatening ventricular arrhythmias such as sustained ventricular tachycardia. יירשם ע"י רופא קרדיולוג
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת
מידע נוסף